{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.2","value":"1750"},{"groupId":"OG001","spread":"61.3","value":"2060"},{"groupId":"OG002","spread":"113","value":"2960"},{"groupId":"OG003","spread":"29.2","value":"4320"},{"groupId":"OG004","spread":"63.1","value":"1100"},{"groupId":"OG005","spread":"107","value":"974"},{"comment":"Geometric Mean and Geometric Coefficient of Variation couldn't be calculated as there was only one participant. Individual value reported: 3270 ng/mL","groupId":"OG006","spread":"NA","value":"NA"},{"groupId":"OG007","spread":"39.6","value":"2670"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"14"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"32.9","value":"1770"},{"groupId":"OG001","spread":"105","value":"2310"},{"groupId":"OG002","spread":"87.5","value":"4270"},{"groupId":"OG003","spread":"17.2","value":"4610"},{"groupId":"OG004","spread":"72.2","value":"1340"},{"groupId":"OG005","spread":"170","value":"1060"},{"groupId":"OG007","spread":"58.2","value":"3200"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"15"}],"units":"Participants"}],"title":"Cycle 2 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"15"}],"units":"Participants"}],"description":"PK: Cmax of LY3475070","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received 150mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.","id":"OG000","title":"Cohort A - 150mg QD LY3475070"},{"description":"Participants received 300mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.","id":"OG001","title":"Cohort A - 300mg QD LY3475070"},{"description":"Participants received 300mg LY3475070 orally twice daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.","id":"OG002","title":"Cohort A - 300mg BID LY3475070"},{"description":"Participants received 600mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.","id":"OG003","title":"Cohort A - 600mg QD LY3475070"},{"description":"Participants received 150mg LY3475070 orally once daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.","id":"OG004","title":"Cohort B - 150mg QD LY3475070 + Pembrolizumab"},{"description":"Participants received 150mg LY3475070 orally twice daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.","id":"OG005","title":"Cohort B - 150mg BID LY3475070 + Pembrolizumab"},{"description":"Participants received 300mg LY3475070 orally once daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.","id":"OG006","title":"Cohort B - 300mg QD LY3475070 + Pembrolizumab"},{"description":"Participants received 300mg LY3475070 orally twice daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study","id":"OG007","title":"Cohort B - 300mg BID LY3475070 + Pembrolizumab"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All enrolled participants in phase1a who received LY3475070 and had intensively sampled evaluable PK data on cycle 1 day 1, cycle 2 day 1 for this outcome. For \"Cohort B - 300mg QD LY3475070 + pembrolizumab,\" the participant has not received the treatment on cycle 2 day 1, and did not meet the analysis criteria. Thus, zero participants were analysed.","reportingStatus":"POSTED","timeFrame":"Day 1 of Cycles 1 and 2 (Pre-dose, 0.5, 1, 2, 4, 6, 8, 24 hours post-dose for the QD arms; Pre-dose, 0.5, 1, 2, 4, 6, 8 hours post-dose for the BID arms)","title":"PK: Maximum Concentration (Cmax) of LY3475070","type":"SECONDARY","unitOfMeasure":"ng/mL"}